Krauskopf Julian, de Kok Theo M, Schomaker Shelli J, Gosink Mark, Burt Deborah A, Chandler Patricia, Warner Roscoe L, Johnson Kent J, Caiment Florian, Kleinjans Jos C, Aubrecht Jiri
Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands.
Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, United States of America.
PLoS One. 2017 May 17;12(5):e0177928. doi: 10.1371/journal.pone.0177928. eCollection 2017.
MicroRNAs (miRNAs) released into the peripheral circulation upon cellular injury have shown a promise as a new class of tissue-specific biomarkers. We were first to demonstrate that next-generation sequencing analysis of serum from human subjects with acetaminophen-induced liver injury revealed a specific signature of circulating miRNAs. We consequently hypothesized that different types of hepatic liver impairments might feature distinct signatures of circulating miRNAs and that this approach might be useful as minimally invasive diagnostic "liquid biopsies" enabling the interrogation of underlying molecular mechanisms of injury in distant tissues. Therefore we examined serum circulating miRNAs in a total of 72 serum samples from a group of 53 subjects that included patients with accidental acetaminophen overdose, hepatitis B infection, liver cirrhosis and type 2 diabetes as well as gender- and age-matched healthy subjects with no evidence of liver disease. The miRNA signatures were identified using next-generation sequencing that provided analysis for the whole miRNome, including miRNA isoforms. Compared to the healthy subjects, a total of 179 miRNAs showed altered serum levels across the diseased subjects. Although many subjects have elevated alanine aminotransferase suggesting liver impairments, we identified distinct miRNA signatures for different impairments with minimum overlap. Furthermore, the bioinformatics analysis of miRNA signatures revealed relevant molecular pathways associated with the mechanisms of toxicity and or pathogenesis of disease. Interestingly, the high proportion of miRNA isoforms present in the respective signatures indicated a new level of complexity in cellular response to stress or disease. Our study demonstrates for the first time that signatures of circulating miRNAs show specificity for liver injury phenotypes and, once validated, might become useful for diagnosis of organ pathologies as "liquid biopsies".
细胞损伤时释放到外周循环中的微小RNA(miRNA)已显示出有望成为一类新的组织特异性生物标志物。我们首先证明,对乙酰氨基酚诱导的肝损伤患者血清进行下一代测序分析,揭示了循环miRNA的特定特征。因此,我们推测不同类型的肝损伤可能具有不同的循环miRNA特征,并且这种方法可能作为微创诊断“液体活检”有用,能够探究远处组织损伤的潜在分子机制。因此,我们检测了一组53名受试者的72份血清样本中的血清循环miRNA,这些受试者包括对乙酰氨基酚意外过量患者、乙型肝炎感染患者、肝硬化患者和2型糖尿病患者,以及性别和年龄匹配且无肝病证据的健康受试者。使用下一代测序鉴定miRNA特征,该测序为整个miRNA组提供分析,包括miRNA亚型。与健康受试者相比,共有179种miRNA在患病受试者中血清水平发生改变。尽管许多受试者丙氨酸转氨酶升高提示肝损伤,但我们鉴定出不同损伤的独特miRNA特征,重叠最少。此外,miRNA特征的生物信息学分析揭示了与疾病毒性和/或发病机制相关的分子途径。有趣的是,各个特征中存在的高比例miRNA亚型表明细胞对应激或疾病反应的新复杂程度。我们的研究首次证明,循环miRNA特征对肝损伤表型具有特异性,一旦得到验证,可能作为“液体活检”用于器官病理诊断。